Claims for Patent: 7,612,182

Summary for Patent: 7,612,182

Title:	Anti-IL-6 antibodies, compositions, methods and uses
Abstract:	The present invention relates to at least one novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies derived from the murine CLB-8 antibody, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Inventor(s):	Giles-Komar; Jill (Downingtown, PA), Knight; David (Berwyn, PA), Peritt; David (Bala Cynwyd, PA), Trikha; Mohit (Paoli, PA)
Assignee:	Centocor, Inc. (Malvern, PA)
Application Number:	11/832,323
Patent Claims:	1. An isolated antibody or antibody fragment that binds to human IL-6, comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:7, a light chain variable region having the amino acid sequence of SEQ ID NO:8, and a constant region derived from one or more human antibodies. 2. An isolated antibody or antibody fragment that binds to human IL-6, comprising the heavy chain and light chain complementarity determining regions (CDRs) having the amino acid sequences of SEQ ID NOS:1-6, and a constant region derived from one or more human antibodies. 3. An IL-6 antibody or antibody fragment according to claim 1, wherein said antibody or antibody fragment binds IL-6 with an affinity (Kd) of at least 10.sup.-9M. 4. An IL-6 antibody or antibody fragment according to claim 1 or 2, wherein said antibody or specified portion or variant substantially neutralizes at least one activity of at least one IL-6. 5. An IL-6 antibody or antibody fragment according to claim 4, wherein said activity is at least one selected from the group consisting of inhibition of IgM mu secretion from SKW6.4 cells, inhibition of IL-6 mediated MCP-1 production, inhibition of IL-6 signaling in THP-1 human monocytic leukemia cells, inhibition of IL-6 induced serum amyloid A production from HepG2 cells, and inhibition of rhIL-6 induced cell proliferation. 6. An IL-6 antibody composition or antibody fragment composition, comprising an isolated IL-6 antibody or antibody fragment according to claim 1 or 2, and a carrier or diluent. 7. A composition according to claim 6, further comprising at least one compound or protein selected from at least one of a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflamatory drug (SNAID), an analgesic, an anesthetic, a sedative, a local anethetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, a diabetes related agent, a mineral, a nutritional, a thyroid agent, a vitamin, a calcium related hormone, an antidiarrheal, an antitussive, an antiemetic, an antiulcer, a laxative, an anticoagulant, an erythropieitin, a filgrastim, a sargramostim, an immunication, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, an estrogen receptor modulator, a mydriatic, a cycloplegic, an alkylating agent, an antimetabolite, a mitotic inhibitor, a radiopharmaceutical, an antidepressant, antimanic agent, an antipsychotic, an anxiolytic, a hypnotic, a sympathomimetic, a stimulant, donepezil, tacrine, an asthma medication, a beta agonist, an inhaled steroid, a leukotriene inhibitor, a methylxanthine, a cromolyn, an epinephrine or analog, dornase alpha, a cytokine, a cytokine antagonist. 8. A formulation comprising at least one IL-6 antibody or antibody fragment according to claim 1 or 2, and at least one selected from sterile water, sterile buffered water, or at least one preservative selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride, alkylparaben, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, ormixtures thereof, in an aqueous diluent. 9. A formulation of claim 8, wherein the concentration of IL-6 antibody or antibody fragment is about 0.1 mg/ml to about 100 mg/ml. 10. A formulation of claim 8, further comprising an isotonicity agent. 11. A formulation of claim 8, further comprising a physiologically acceptable buffer. 12. A formulation comprising at least one IL-6 antibody or antibody fragment according to claim 1 or 2 in lyophilized form in a first container, and an optional second container comprising sterile water, sterile buffered water, or at least one preservative selected from the group consisting of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride, alkylparaben, benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal, or mixtures thereof in an aqueous diluent. 13. A formulation of claim 12, wherein the concentration of IL-6 antibody or antibody fragment is reconsituted to a concentration of about 0.1 mg/ml to about 500 mg/ml. 14. A formulation of claim 12, further comprising an isotonicity agent. 15. A formulation of claim 12, further comprising a physiologically acceptable buffer.

Details for Patent 7,612,182

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	02/20/1991		2039-02-26
Amgen, Inc.	NEUPOGEN	filgrastim	Injection	103353	06/28/2000		2039-02-26
Partner Therapeutics, Inc.	LEUKINE	sargramostim	For Injection	103362	03/05/1991		2039-02-26
Partner Therapeutics, Inc.	LEUKINE	sargramostim	Injection	103362	03/05/1991		2039-02-26
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2039-02-26